Skip to content
Search

Latest Stories

'Holmes is not a villain, but her company failed,' defense says during Theranos trial

'Holmes is not a villain, but her company failed,' defense says during Theranos trial

THERANOS founder Elizabeth Holmes is not a villain but rather a hard-working, young and naive businesswoman whose company simply failed, her lawyer told jurors on Wednesday (8) at the former Silicon Valley star's trial on fraud charges involving the now-defunct blood-testing startup once valued at $9 billion.

Federal prosecutors and defense lawyers painted remarkably different portraits of Holmes in their opening statements to the 12-member jury in one of the most closely watched trials of an American corporate executive in years. The prosecution then called its first witness, a former company executive.


Robert Leach, one of the prosecutors, said Holmes had engaged in a scheme of "lying and cheating" to attain wealth and fame at the expense of investors and patients.

Holmes is accused of making false claims about Theranos, including that its devices - designed to draw a drop of blood from a finger prick - could run a range of tests more quickly and accurately than conventional laboratory means.

"In the end, Theranos failed and Holmes walked away with nothing," defense lawyer Lance Wade told jurors in San Jose, California.

"But failure is not a crime. Trying your hardest and coming up short is not a crime. And by the time this trial is over, you will see that the villain the government just presented is actually a living, breathing human being who did her very best each and every day. And she is innocent," Wade added.

Holmes, 37, has pleaded not guilty to 10 counts of wire fraud and two counts of conspiracy. She may testify during the trial, which resumes on Friday (10) with more witness testimony.

"This is a case about fraud - about lying and cheating to get money," prosecutor Leach told jurors.

"The scheme brought her fame, it brought her honour and it brought her adoration," Leach added, also making her a billionaire.

"She had become, as she sought, one of the most celebrated CEOs in Silicon Valley and the world. But under the facade of Theranos' success there were significant problems brewing," Leach said.

The defense disagreed. Wade told jurors: "Elizabeth Holmes did not go to work every day intending to lie, cheat and steal. The government would have you believe her company, her entire life, is a fraud. That is wrong."

On paper, Theranos was worth billions of dollars, but when Holmes left it in 2018, her savings, stock and company were "all gone," Wade said.

Wade asked jurors to ponder whether Theranos failed because its technology was a fraud or "because a young CEO and her company confronted and could not overcome business obstacles that others saw but she naively underestimated."

Wade said Holmes dropped out of prestigious Stanford University at age 19 and bet her savings to start Theranos in 2003, then poured her life into it for 15 years. Holmes grabbed headlines with her vision of a small machine that could run blood tests in stores and homes.

"She was all in on Theranos, motivated by its mission, not money, committed to that mission until that very last day," Wade said.

Former Theranos executive Ramesh "Sunny" Balwani, scheduled to be tried separately, also has pleaded not guilty. Court filings showed that Holmes, who had a romantic relationship with Balwani, has said he abused her emotionally and psychologically - allegations he denies.

One of her mistakes, Wade told jurors, was "trusting and relying on Balwani as her primary adviser."

Prosecutors have said Holmes and Balwani defrauded investors between 2010 and 2015 and deceived patients when Theranos began making its tests commercially available, including a partnership with the Walgreens drugstore chain.

Leach said Holmes agreed with Balwani to carry out the scheme. In 2009, after losing interest from Pfizer Inc and other pharmaceutical companies, Holmes turned to fraud, Leach said.

"Out of time and out of money, Elizabeth Holmes decided to lie," Leach said.

(Reuters)

More For You

7 biggest moments at Glastonbury 2025 from Pulp reunion buzz to Kneecap controversy

Glastonbury 2025 delivers heat drama and mystery with Pulp reunion rumours and Kneecap row

Getty Images

7 biggest moments at Glastonbury 2025 from Pulp reunion buzz to Kneecap controversy

You think you're coming to Glastonbury for the music. That’s what you tell yourself. But then, by Day 4, it’s Saturday afternoon, the sun’s hammering down like it’s got a personal vendetta against pasty Brits, and the air’s thick with sunscreen, spilled cider, and pure anticipation.

Something big’s brewing. Something secret. Something that makes you feel like you're standing on the edge of history, or at least a really, really good party. There’s joy and rebellion here. Tears and beer. Political fire and surprise reunions.

Keep ReadingShow less
modi-trump-getty
Trump shakes hands with Modi during a joint press conference at Hyderabad House in New Delhi on February 25, 2020. (Photo: Getty Images)

Key issues in India, US trade talks

TRADE talks between India and the US have hit a roadblock over disagreements on duties for auto components, steel and farm goods, Indian government sources said to Reuters, dashing hopes of reaching an interim deal ahead of president Donald Trump's July 9 deadline to impose reciprocal tariffs.

Here are the key issues at play:

Keep ReadingShow less
Harris Dickinson Bond rumors

Tom Holland Jacob Elordi and Harris Dickinson top James Bond shortlist as Amazon eyes younger 007

Getty Images

Tom Holland, Harris Dickinson and Jacob Elordi among top picks for 'James Bond' as Amazon begins new 007 era

Quick highlights:

  • Amazon’s reboot of the James Bond franchise is in early stages, with Dune director Denis Villeneuve attached.
  • Insiders claim Tom Holland, Jacob Elordi and Harris Dickinson are top contenders for the new 007.
  • The studio is reportedly seeking a British actor under 30; no official casting decisions made yet.
  • Next Bond film is unlikely to release before 2028 due to scheduling and production timelines.

The race for the next James Bond is heating up, and three familiar faces are at the top of the list.

Keep ReadingShow less
Kanpur 1857 play

This summer, Niall Moorjani returns to the Edinburgh Festival Fringe with 'Kanpur: 1857'

Pleasance

Niall Moorjani brings colonial history to life with powerful new play 'Kanpur: 1857'

This summer, Niall Moorjani returns to the Edinburgh Festival Fringe with Kanpur: 1857, an explosive new play that fuses biting satire, history and heartfelt storytelling. Written, co-directed and performed by Moorjani, alongside fellow actor and collaborator Jonathan Oldfield, the show dives into the bloody uprising against British colonial rule in 1857 India, focusing on the brutal events in Kanpur.

At its centre is an Indian rebel, played by Moorjani, strapped to a cannon and forced to recount a version of events under the watchful eye of a British officer.

Keep ReadingShow less
Alcaraz &  Djokovic

Djokovic (L) and Alcaraz embrace during practice prior to The Championships Wimbledon 2025 at All England Lawn Tennis and Croquet Club on June 26.

Getty

Wimbledon 2025: Alcaraz eyes third straight title as Sinner, Djokovic lead challenge

CARLOS ALCARAZ will look to win his third consecutive Wimbledon title this year, reinforcing his position as the leading player on all surfaces. Jannik Sinner, who lost to Alcaraz in a closely fought French Open final, heads to London hoping to reverse the result.

Seven-time Wimbledon champion Novak Djokovic will also be in contention. At 38, this could be his best chance to win a record 25th Grand Slam title. Djokovic lost the last two Wimbledon finals to Alcaraz and will aim to reclaim the trophy at the All England Club.

Keep ReadingShow less